Conclusion
In summary, our case report supports the use of eculizumab as an emergency therapy in refractory life-threatening wAIHA especially if DAT is positive for both IgG and C3d, even if related to underlying hematological malignancy and after failure of conventional therapies. However, this treatment is suspensive and should only be considered as a transient salvage treatment. Optimal duration, dosage and frequency of administration are unknown.